Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Urology Annals. 2015; 7 (1): 115-119
in English | IMEMR | ID: emr-154923

ABSTRACT

Primary sarcoma of the prostate is extremely rare and accounts for 0.1% of all prostate cancers. This type of cancer is associated with poor prognosis due to aggressive biological behavior. The World Health Organization histologically classified prostate sarcomas as stromal tumor of unknown malignant potential [STUMP] and stromal sarcoma. A 39-year-old patient presented with lower urinary tract symptoms over the last few months. On digital rectal examination, the right lobe of the prostate was diffusely hard on palpation. Prostate-specific antigen was 0.5 ng/ml. A biopsy specimen was obtained with the guidance of transrectal ultrasonography. Immunohistochemical examination revealed positive staining for vimentin, actin, and desmin. [18] F-fluorodeoxyglucose-positron-emission tomography/computed tomography scans obtained for staging purposes with the diagnosis of primary spindle cell carcinoma of the prostate revealed widespread lung and liver metastases. A doxorubicin-based systemic chemotherapy [CTx] was initiated. Spindle sarcomas of the prostate have quite aggressive nature and they have high potential to metastase. Average life expectancy is <1 year and the prognosis is poor. CTx and radiation therapy can't yield curative effects due to poor differentiation


Subject(s)
Humans , Male , Sarcoma , Fluorodeoxyglucose F18 , Positron-Emission Tomography , Tomography, X-Ray Computed
2.
Journal of Pathology and Translational Medicine ; : 389-395, 2015.
Article in English | WPRIM | ID: wpr-182011

ABSTRACT

BACKGROUND: Parafibromin is a recently defined tumor suppressor gene. The aim of our study was to determine the relationships of parafibromin expression in urothelial carcinomas (UCs) with prognostic parameters and to evaluate the use of parafibromin as a potential marker of UC. METHODS: Parafibromin expression was assessed in 49 UC specimens using immunohistochemistry. The correlations between parafibromin expression and clinical and pathologic parameters were investigated. RESULTS: Of the patients, 42 (85.7%) were male, and the mean age was 69.6 +/- 8.2 years (range, 54 to 88 years). Morphologically, the UCs were divided into two groups: papillary (n = 27) and non-papillary (n = 22). There were seven low-grade (14.3%) and 42 high-grade (85.7%) tumors. Parafibromin was negative in 13 tumors (26.5%), partially positive in 19 tumors (38.8%), and positive in 17 tumors (34.7%). Parafibromin expression was more negative in UCs from upper urinary locations (n=17) and with muscularis propria invasion (n=28), which was statistically significant (p = .009 and p = .007, respectively). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, survival, or disease-free survival. CONCLUSIONS: We found that UC cases with parafibromin positivity had less of a tendency to show muscularis propria invasion and were more commonly located in the lower urinary system. These results need to be confirmed with studies based on larger case series.


Subject(s)
Humans , Male , Disease-Free Survival , Genes, Tumor Suppressor , Immunohistochemistry
3.
Cancer Research and Treatment ; : 834-843, 2015.
Article in English | WPRIM | ID: wpr-90556

ABSTRACT

PURPOSE: The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) to detection of metastatic bladder cancer. MATERIALS AND METHODS: The present study included 79 patients (69 men and 10 women) undergoing 18F-FDG-PET/CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85 years). Patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after intravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. RESULTS: The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. CONCLUSION: 18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive values in patients with metastatic bladder carcinoma.


Subject(s)
Humans , Male , Fluorodeoxyglucose F18 , Follow-Up Studies , Injections, Intravenous , Neoplasm Metastasis , Positron-Emission Tomography , Retrospective Studies , Sensitivity and Specificity , Skull Base , Thigh , Tomography, X-Ray Computed , Urinary Bladder Neoplasms , Urinary Bladder
4.
International Neurourology Journal ; : 45-47, 2014.
Article in English | WPRIM | ID: wpr-180776

ABSTRACT

No abstract available.

SELECTION OF CITATIONS
SEARCH DETAIL